Oncology DRUG Intelligence
Provides Complete Landscape on Latest Oncology Drug Development covering Emerging Technologies, Partnering and Funding Status in the Domain.
Drug Developers with proper funding, technologies and pipeline are only included. No Acquired, Merged or Dormant Stage Cancer Targeting Drug Developer is included.
providing intelligence at fingertips
Worldwide 38 Countries Covered. Largest Coverage Guaranteed
Includes 1250 Clinical Stage & 1250 Early Stage Oncology Drug Discovery Companies
Includes – Individual Drug Mechanism of Action & Drug Targets.
Covers complete Emerging Cancer Drug Targets Details with Numerous Technologies
Intelligence @ fingertips
identify new opportunities
Unique first in class Intelligence Report
Comparisons | Oncology Drug Intelligence 2024 | Other Intelligence Sources |
|---|---|---|
Clinical Stage Oncology Drug Developers | 1250 Clinical Stage Drug Discovery Companies (Include only well funded companies with valid Pipeline ) | 800-1000 Clinical Stage Companies (may also contain closed, acquired or merged companies) |
Pre-Clinical Stage Oncology Drug Developers | 1250 Preclinical Stage Drug Discovery Companies (Include only well funded companies with valid Pipeline ) | 400-600 Startup Companies (may include inactive and other domain companies) |
Worldwide Coverage | 38 Countries Included (51% USA, 23% Europe, 21% Asia and 5% ROW) | Mainly focuses on United States & Europe |
Oncology Drugs in Development | 4800+ Onco Targeting Drugs in Active Development(2800+ Clinical Stage with NCT Number & 2000+ Preclinical Stage, with their Targets and mechanism of Action) | 2000 – 2500 Onco Targeting Drugs (mainly includes Clinical Stage molecules in development) |
Bio-Partnering Details | 1700+ Oncology Deals complete Details.(Complete coverage on Oncology focused Deals, & Partnering Activities) | Limited to Database Subscribed to.(It may require to map events between two or more different resources and manually filter Onco Linked Deals). |
Trusted by
